Trial · NCT03600441
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
NCT03600441, Phase 2, Active not recruiting, Xynomic Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma. Trials, record NCT03600441. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03600441
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
- NCT number
- NCT03600441
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 139 participants, estimated
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.
- Conditions
- Follicular Lymphoma
- Interventions
- Abexinostat
- First posted
- 2018-07-26
- Last updated
- 2025-04-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical effect of abexinostat | Time frame up to 100 months | Complete response (CR) or partial response (PR) according to the Lugano 2014 criteria as determined by an Independent Review Committee (IRC). |
| Secondary | Duration of response | At the end of cycle 2 (each cycle is 28 days) and through study completion, assessed up to 100 months. | Duration of response defined as the time from first documented evidence of CR or PR until disease progression or death from any cause among patients who achieve an objective response, according to the Lugano 2014 criteria as determined by an IRC. |
| Secondary | Progression free survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Defined as the time from the start of treatment until disease progression or death assessed using the Lugano 2014 criteria as determined by an IRC. |
| Secondary | Clinical Benefit | At the end of cycle 2 (each cycle is 28 days) and through study completion, assessed up to 100 months. | Defined as the best from CR, PR, or stable disease (SD) according to the Lugano 2014 criteria as determined by an IRC. |
| Secondary | Overall survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Defined as the time from the start of treatment until death from any cause or last contact. |
| Secondary | Duration of response | At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Defined as the time from first documented evidence of CR or PR from any cause among patients who achieve an objective response, according to the RECIL 2017 as determined by an IRC. Duration of response will be evaluated once more using the RECIL 2017 with the inclusion of Minor Response (MR) lasting ≥ 6 months. |
| Secondary | Incidence of adverse events | At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Safety as measured by the incidence of adverse events |
| Secondary | Incidence of serious adverse events | At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Safety as measured by the serious of adverse events (SAE) |
| Secondary | Incidence of non-serious adverse events | At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Safety as measured by the non-serious of adverse events |
| Secondary | Change in the interval corrected for heart rate (QTc) interval | At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months | Change from baseline in the QTc interval. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03600441
GET https://conductscience.org/api/trials/v1/NCT03600441/registered